New Stock News | Bangshun Pharma files to list on Hong Kong Stock Exchange

18:35 22/01/2026

According to the disclosure on January 22 by the Hong Kong Stock Exchange, Hangzhou Bangshun Pharmaceutical Co., Ltd. has submitted its application for listing on the main board of the Hong Kong Stock Exchange, with Citic Securities International as its sole sponsor.

According to the disclosure on January 22 by the Hong Kong Stock Exchange, Hangzhou Bangshun Pharmaceutical Co., Ltd. (hereinafter referred to as Bangshun Pharmaceutical) submitted an application for listing on the main board of the Hong Kong Stock Exchange, with China Securities Co., Ltd. as its exclusive sponsor. The prospectus shows that Bangshun Pharmaceutical is a biotechnology company close to the commercialization stage, focusing on the areas of tumors and autoimmune diseases. The company has established a pipeline covering a new drug application (NDA) stage candidate drug (Bezusitini), a registration clinical stage candidate drug (CX1440) and five pre-clinical stage candidate drugs (CX03, CX12, CX13, CX15 and CX16).

ZHONGZHIPHARM(03737) issues a profit warning, expecting a decrease in annual net profit of no less than 70%.

SUNHO BIO-B(02898): Jiang Xiaoling appointed as Chief Executive Officer and Chief Scientific Officer

RIMAG GROUP (02522) has issued 6.13 million H shares of bonus shares.

ZHONGZHIPHARM(03737) issues a profit warning, expecting a decrease in annual net profit of no less than 70%.

SUNHO BIO-B(02898): Jiang Xiaoling appointed as Chief Executive Officer and Chief Scientific Officer

RIMAG GROUP (02522) has issued 6.13 million H shares of bonus shares.